Q-omics provides the consensus-scored NFKB1 profile across patient tissues and cancer cell-line models. NFKB1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NFKB1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NFKB1 protein abundance shows 30,305 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where NFKB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NFKB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NFKB1 survival associations across molecular data types. NFKB1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NFKB1 RNA expression–survival associations across cancer types. High NFKB1 expression shows unfavorable associations in LGG and UVM, but favorable associations in KIRC, READ, SKCM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NFKB1 RNA expression.
This table summarizes NFKB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NFKB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NFKB1 shows lower tumor expression in BLCA and THCA and higher tumor expression in KIRC, HNSC, STAD and LIHC. The KIRC box plot shows higher NFKB1 RNA expression in tumor versus normal tissue (log2 FC = +0.753, t-test p < 0.001).
This table shows molecular features associated with NFKB1 in patient tissues and cancer cell lines. In patient samples, NFKB1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NFKB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
